Measurement of vanilloïd Compounds in Urin of Autistic vs Control Patients, as Potential Biomarkers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

140 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-12-15

Study Completion Date

2022-07-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In a former study, four vanilloid compounds were observed increased in the urin of autistic patients. The present study is aimed at performing a ambispective study to confirm or not these preliminary results. 70 urins from autistic children (already collected) will be compared to 70 urins of non autistic children (collected without intervention, remaining sample from the standard care), in terms of measurements of four vanilloid compounds using a GCMS apparatus.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Autism Spectrum Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

For cases :

* Male children aged 2 years to less than 15 years inclusive years at time of sample collection
* Children with a diagnosis of autism (ICD-10 F84.0) after assessment by a child psychiatrist.

For healthy chlidren:

* Children aged 2 years to less than 15 years old performing an ECBU at the CHRU of Nancy as part of their care.
* Patient whose ECBU is negative with respect to cytobacteriology (absence of urinary infection).
* Child can be matched to a CAS

Exclusion Criteria

For cases:

* Children in whom one of the following pathologies is found during the anamnesis or in the clinical record : (i) renal insufficiency; (ii) urinary tract infection at the time of sampling and/or metabolic disease
* Children on antibiotic treatment at the time of collection

For healthy chlidren :

* children whose urine culture come from one of the following departments: Pediatric Nephrology (potential risk of renal failure) or Pediatric Neurology (potential risk of neurological disorder).
* with a diagnosis of autism
* with a metabolic disease
* children undergoing antibiotic treatment at the time of collectio

Minimum Eligible Age

2 Years

Maximum Eligible Age

14 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Marc MERTEN

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jean-Luc Olivier, MD, PhD,

Role: STUDY_DIRECTOR

CHRU Nancy

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Marc Merten, PhD

Role: CONTACT

Phone: 33 616 364 916

Email: [email protected]

Jean-Luc Olivier, MD, PhD, Pr